AbbVie ABBV over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

As pharmaphorum recently reported, the entrance of biosimilars to Humira is a significant event for a number of reasons, not least because the drug is the top-selling pharmaceutical product of all ...

Humira is a self-injectable treatment used for a number of autoimmune disorders. Biosimilars reference originator biologics such as Humira. To gain approval by the the Food and Drug Administration ...

While there are already a number of biosimilars of AbbVie's big-selling Humira on the US market, so far, only one – Boehringer Ingelheim's Cyltezo – is interchangeable with the original ...

Rebating played a role, with the originator company AbbVie giving large sums to PBMs to keep Humira on formulary or maintain its preferred status. The situation is changing, as the number of new ...

Humira is used to treat certain inflammatory conditions. It’s mainly covered by Medicare Part D when self-administered or, more rarely, by Part B when administered by a doctor. Humira ...

Some parts of Medicare, including Part B and Part D, may cover the approved drug Humira (adalimumab). However, some Medicare Advantage plans may also offer coverage. Humira contains the active ...